Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rotigotine Transdermal System Clear all
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042
View directory record Official record
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

NCT02727205
View directory record Official record
Conditions
Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions
Rotigotine Transdermal System
Drug
Lead sponsor
Inflamax Research Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003, Neupro 4Mg/24Hr Transdermal Patch
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 2, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 2, 2026, 8:15 PM EDT
Completed No phase listed Observational

Named Patient Program With Rotigotine Transdermal System

NCT01095484
View directory record Official record
Conditions
Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine
Interventions
Rotigotine patch
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
51
States / cities
Birmingham, Alabama • Cullman, Alabama • Fairhope, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

NCT03992196
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Treatment of Parkinson's Disease With a Transdermal Skin Patch

NCT00001931
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-0923
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 8:15 PM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

NCT00474058
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

NCT00242008
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

NCT04384666
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch
Drug · Other
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

NCT00522379
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
30 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model

NCT02123979
View directory record Official record
Conditions
Post-op Pain
Interventions
Neupro® transdermal patch/placebo
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 2, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

NCT05886582
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Rotigotine Transdermal System [Neupro], Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
25 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 8:15 PM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870
View directory record Official record
Conditions
Anxiety Disorders, Parkinson Disease
Interventions
rotigotine transdermal patch, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 2, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 2, 2026, 8:15 PM EDT